Unspecified

Extract from the above information

Broad-spectrum antiviral drug. It has the effect of inhibiting the growth of multiple viruses such as respiratory syncytial virus, influenza virus, hepatitis A virus, adenovirus, etc. in vitro, and its mechanism is not fully understood. After entering the virus-infected cells, the drug is rapidly phosphorylated, and its product acts as a competitive inhibitor of viral synthase, inhibiting inosine monophosphate dehydrogenase, influenza virus RNA polymerase and mRNA guanosine transferase, thereby causing a decrease in intracellular guanosine triphosphate, impairing viral RNA and protein synthesis, and inhibiting viral replication and transmission. It may also have an immune effect and neutralizing antibody effect on respiratory syncytial virus.

By protecting the energy metabolism of cells under hypoxia or ischemia, preventing the decrease of intracellular ATP levels, thus ensuring the normal function of ion pumps and the normal operation of transmembrane sodium-potassium flow, and maintaining the stability of the intracellular environment. 1 Helps maintain the energy metabolism of the heart and nerve sensory organs under ischemia and hypoxia. 2 Reduces intracellular acidosis and changes in transmembrane ion flow caused by ischemia. 3 Reduces the movement and infiltration of multinuclear neutrophils during ischemia and myocardial reperfusion, and reduces the scope of experimental infarction. 4 While producing this effect, it has no significant effect on hemodynamics. Human studies have shown that trimetazidine can: 1 Increase coronary blood flow reserve, thereby delaying the occurrence of exercise-induced ischemia from the 15th day of treatment. 2 Limit rapid fluctuations in blood pressure without significant changes in heart rate. 3 Significantly reduce the frequency of angina attacks. 4 Significantly reduce the use of glyceryl trinitrate.